Appealing Off-Label Keytruda Coverage Denials

Understanding Off-Label Cancer Drug Coverage

Many cancer drugs are used for indications not specifically listed on the FDA label. Federal and state laws often REQUIRE coverage of off-label cancer drugs when supported by recognized compendia:

• NCCN Drugs & Biologics Compendium — most widely recognized
• Elsevier Clinical Pharmacology (formerly Gold Standard)
• Micromedex DrugDex

Building Your Keytruda Off-Label Appeal

Step 1: Verify Compendia Support

Check if your specific cancer type and biomarker profile is listed in NCCN Guidelines or the NCCN Compendium. Even a Category 2A recommendation provides strong support.

Step 2: Gather Clinical Evidence

• Published clinical trial results supporting efficacy
• Peer-reviewed journal articles
• Conference presentations (ASCO, ESMO)
• Case reports or series

Step 3: Biomarker Documentation

• PD-L1 expression (TPS or CPS score)
• MSI-H/dMMR status
• TMB (tumor mutational burden)
• Other relevant biomarkers

Step 4: Your Oncologist's Letter

Should reference specific NCCN guideline section, clinical evidence, patient's biomarker profile, and why alternative FDA-approved options are not appropriate.

Legal Requirements

Many states mandate coverage of NCCN-supported cancer drugs. Medicare covers drugs in approved compendia. Check your state's off-label drug coverage laws.